SCHEMBL3014375

SCHEMBL3014375

O=S(=O)(c1cccc(Br)c1)N1CCN(c2nc(-c3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPT P10636 5/20 0.51
USP2 O75604 2/20 0.51
HSD17B10 Q99714 2/20 0.51
RECQL P46063 1/20 0.51
LMNA P02545 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 2/20 0.48
GBA1 P04062 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020227 0.93 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3016680 0.92 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3012183 0.91 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3022783 0.90 MAPT (0.55) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3010391 0.89 MAPT (0.59) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3015607 0.89 KDM1A (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3001235 0.89 AR (0.55) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3011304 0.89 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3004740 0.89 LMNA (0.63) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3000007 0.88 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.